You are here

  • Home
  • Archive
  • Volume 68, Issue Suppl 2
  • OTU-14 Positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH

Article Text

Article menu

Download PDFPDF

Liver
Orals
OTU-14 Positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH
Free
  1. Zobair Younossi1,
  2. Vlad Ratziu2,
  3. Rohit Loomba3,
  4. Mary Rinella4,
  5. Quentin M Anstee5,
  6. Luna Zaru6,
  7. Leigh MacConell6,
  8. Reshma Shringarpure6,
  9. Stephen Harrison7,
  10. Arun Sanyal8
  1. 1Betty and Guy Beatty Center for Integrated Research,Inova Health System, Falls Church, USA
  2. 2Sorbonne Université Hôpital Pitié – Salpêtrière, Paris, France
  3. 3University of California San Diego, San Diego, USA
  4. 4Feinberg School of Medicine, Northwestern University, Chicago, USA
  5. 5Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK
  6. 6Intercept Pharmaceuticals, San Diego, USA
  7. 7Pinnacle Clinical Research Center, San Antonio, USA
  8. 8Virginia Commonwealth University, Richmond, USA

Abstract

Introduction Obeticholic acid (OCA), an FXR agonist, improved both fibrosis and histologic features of nonalcoholic steatohepatitis (NASH) in the Ph2 FLINT study. This Month 18 pre-specified interim analysis of the ongoing Ph3 REGENERATE study evaluated the effect of OCA on liver histology in patients (pts) with biopsy-confirmed NASH.

Methods Pts with NASH and fibrosis stages F2–3 (ITT), and an exploratory group of F1 pts with metabolic syndrome, were randomized to placebo (PBO), OCA 10 mg, or OCA 25 mg QD. Primary endpoints were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of liver fibrosis. The safety population included all randomized and dosed pts (F1–3, N=1968). Clinical outcomes will be evaluated at the end-of-study.

Results The ITT population included 931 pts (PBO [n=311], OCA 10 mg [n=312] or OCA 25 mg [n=308]), comprised of 44% F2 and 56% F3. Baseline characteristics were well-balanced across groups. Results in table 1. The primary fibrosis endpoint was met by 11.9% PBO, 17.6% OCA 10 mg (p=0.0446), and 23.1% OCA 25 mg (p=0.0002) pts (ITT). The primary NASH endpoint was not statistically significant (ITT); however, in a pre-specified analysis that included F1-F3 pts (N=1218), more OCA 25 mg pts achieved NASH. Pruritus was the most common AE (19% PBO, 28% OCA 10 mg, 51% OCA 25 mg) and was predominantly mild to moderate in severity (severe: <1% PBO, <1% OCA 10 mg, 5% OCA 25 mg). More OCA 25 mg pts discontinued due to pruritus (<1% PBO, <1% OCA 10 mg, 9% OCA 25 mg. SAEs occurred in 11% PBO, 11% OCA 10 mg and 14% OCA 25 mg pts. Increases in LDLc with OCA were observed by Wk 4, but approached baseline by M18 (OCA 25 mg: LS mean change Wk4 +22.6 mg/dL, M18 +4.0 mg/dL). Three deaths occurred; none were considered treatment-related (PBO n=2; OCA 25 mg n=1).

View this table:
Abstract OTU-14 Table 1

Conclusion Treatment with OCA 25 mg improved liver fibrosis, key histologic features of steatohepatitis and liver biochemistry, demonstrating consistent efficacy with an overall AE profile similar to previous studies.

https://doi.org/10.1136/gutjnl-2019-BSGAbstracts.205

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.